Agios to Participate in March Investor Conferences

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the following March investor conferences:

• Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 1:30 p.m. ET; and
• Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023 at 12:00 p.m. ET.

Live webcasts of the presentations can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.agios.com. Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.

About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company’s leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has a PAH stabilizer in preclinical development as a potential treatment for phenylketonuria (PKU) and deep scientific expertise in classical hematology. For more information, please visit the company’s website at www.agios.com.

Investor & Media Contact
Jessica Rennekamp
Senior Director, Corporate Communications
Jessica.Rennekamp@agios.com